Cargando…
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132968/ https://www.ncbi.nlm.nih.gov/pubmed/35614047 http://dx.doi.org/10.1038/s41392-022-01022-x |
| _version_ | 1784713494673752064 |
|---|---|
| author | Luo, Yuejun Sun, Nan He, Jie |
| author_facet | Luo, Yuejun Sun, Nan He, Jie |
| author_sort | Luo, Yuejun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9132968 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91329682022-05-27 Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC Luo, Yuejun Sun, Nan He, Jie Signal Transduct Target Ther Research Highlight Nature Publishing Group UK 2022-05-25 /pmc/articles/PMC9132968/ /pubmed/35614047 http://dx.doi.org/10.1038/s41392-022-01022-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Research Highlight Luo, Yuejun Sun, Nan He, Jie Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC |
| title | Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC |
| title_full | Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC |
| title_fullStr | Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC |
| title_full_unstemmed | Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC |
| title_short | Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC |
| title_sort | nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for escc |
| topic | Research Highlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132968/ https://www.ncbi.nlm.nih.gov/pubmed/35614047 http://dx.doi.org/10.1038/s41392-022-01022-x |
| work_keys_str_mv | AT luoyuejun nivolumabplusipilimumabapotentialregimentorewritetreatmentguidelinesforescc AT sunnan nivolumabplusipilimumabapotentialregimentorewritetreatmentguidelinesforescc AT hejie nivolumabplusipilimumabapotentialregimentorewritetreatmentguidelinesforescc |